drugset / Trial / NCT05242471
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Timeline
- Start
- 2022-07-22
- Primary completion
- 2025-05-23
- Completion
- 2029-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golimumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | — | Subcutaneous |
| Subject | JNJ-78934804 | Unknown | — | Subcutaneous |